bioMérieux: 15.7% organic growth in H1
(CercleFinance.com) - bioMérieux has announced that as at 30 June 2020, its sales reached 1,476 million euros, representing 15.
7% growth excluding FX factors and scope effects, including organic growth of 10.7% in the second quarter.
The group announced, "As expected, adverse impact of the global health crisis on microbiology, immunoassay and industrial applications product lines," as well as "Sustained positive momentum of molecular biology product lines".
The in vitro diagnosis specialist adds that it will will publish its H1 financial results on 2 September, and that its 2020 targets remain suspended due to the lack of visibility regarding the evolution of the health crisis.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
7% growth excluding FX factors and scope effects, including organic growth of 10.7% in the second quarter.
The group announced, "As expected, adverse impact of the global health crisis on microbiology, immunoassay and industrial applications product lines," as well as "Sustained positive momentum of molecular biology product lines".
The in vitro diagnosis specialist adds that it will will publish its H1 financial results on 2 September, and that its 2020 targets remain suspended due to the lack of visibility regarding the evolution of the health crisis.
Copyright (c) 2020 CercleFinance.com. All rights reserved.